ClinicalTrials.gg
TerminatedNCT02072096IMPERIUMUpdated Oct 9, 2019Results posted

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 4 interventional study of Glimepiride and Metformin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Terminated at 34 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Why this study was terminated
The trial was terminated per protocol because of lack of feasibility.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
47th of 151
192 · median 62
Started
2014
with 12 others
Phase 4
48 of 151
1 open now
Registered
94th of 151
by date
Lead sponsor
2 of 151
Eli Lilly and Company

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 47th largest by enrollment, is one of 13 that started in 2014, is one of 48 in phase 4, and was the 94th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T2DM based on a history and clinical impression that is consistent with the World Health Organization (WHO) Classification of Diabetes
  • Have a Clinical Frailty Scale (CFS) score of 4 or above or Total Illness Burden Index (TIBI) score of 5 or above as assessed at screening
  • Have an A1c >7.3% and \<10.9% at study entry and are not achieving desired glycemic control as evidenced by A1c measurement at least 0.4% higher than individualized treatment target set at screening.
  • Have been treated for at least 3 months prior to the study entry with any of the following treatment options:

    • Diet/exercise only (only if they have known to metformin treatment)
    • Any dose of sulfonylurea
    • Effective or maximally-tolerated doses of metformin, dipeptidyl-peptidase-4 (DPP-4) inhibitor, thiazolidinedione, or acarbose used in monotherapy or in dual combination. The following doses are considered to be effective:

      • at least 1500 mg of metformin per day
      • At least 30 mg of pioglitazone per day
      • At least 4 mg of rosiglitazone per day
      • At least 75 mg of acarbose per day
      • Any marketed dose of DPP-4 inhibitor

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in a clinical trial involving an product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated, within the last 60 days in a clinical trial involving an investigational product other than the investigational product used in this study. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
  • Have previously completed or withdrawn from this study. This exclusion criterion does not apply to participants who are rescreened prior to randomization
  • At study entry, have to sulfonylurea, insulin, or GLP-1 RA
  • Have a history of pancreatitis, a personal or family history of medullary thyroid carcinoma, or have Multiple Endocrine Neoplasia syndrome type 2
  • Have taken any injectable glucose-lowering agent, miglitol, meglitinide, Sodium/Glucose cotransporter-2 inhibitor, or other antihyperglycemia treatment that is not listed in the fourth inclusion criterion for more than 10 days within 3 months prior to the study entry
  • In the opinion of investigator should have an individualized A1c target set at 8% or higher
  • Have a (BMI) greater than 45 kg/m\^2
  • Have had more than 1 episode of severe hypoglycemia within 24 weeks prior to the study
  • Have cardiac disease with functional status that is Class III or IV according to the Cardiac Disease Classification
  • Have an estimated (eGFR) \<30 milliliter/minute/1.73 m\^2 (mL/min/1.73 m\^2) or advanced renal disease including history of renal transplantation or currently receiving renal dialysis
  • Have obvious clinical signs or symptoms or laboratory evidence of liver disease ( [ALT] or aspartate aminotransferase [AST] > 2.5 times the upper limit of the reference range)
  • Receive current therapy for a , other than basal-cell or squamous-cell skin cancer
  • Received systemic within the 3 months prior to entry for more than 14 consecutive days
  • Have any other condition that precludes the participant from following and completing the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Strategy A (Glucose-Dependent)

    Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists \[GLP-1 RA\]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.

    Drug: Metformin · Drug: Pioglitazone · Drug: Acarbose · Drug: Linagliptin · Drug: Sitagliptin · Drug: Liraglutide · Drug: Exenatide once weekly (QW) · Drug: Exenatide twice daily (BID)

  • Active comparator
    Strategy B (Reference)

    Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.

    Drug: Glimepiride · Drug: Metformin · Drug: Pioglitazone · Drug: Acarbose · Drug: Linagliptin · Drug: Sitagliptin · Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia

    Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c \> upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c \> upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associated with blood glucose ≤3.9 millimole per liter (mmol/L), or repeated asymptomatic hypoglycemia associated with blood glucose \<3.0 mmol/L. Success is defined as lacking of failure.

    Time frame: Baseline to last participant visit (up to 72 weeks)

Secondary outcomes

  1. Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy

    Time frame: Baseline to last participant visit (up to 72 weeks)

  2. Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia

    Time frame: Baseline to last participant visit (up to 72 weeks)

  3. Change From Baseline of Urinary Albumin to Creatinine Ratio

    The Urinary Albumin to Creatinine Ratio is used in addition to Estimated Glomerular Filtration Rate (eGFR) to measure the incidence and progression of diabetic kidney disease.

    Time frame: Baseline, Week 72

  4. Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 72

  5. Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)

    The eGFR is used in addition to the Urinary Albumin to Creatinine Ratio to measure the incidence and progression of diabetic kidney disease.

    Time frame: Baseline, Week 72

Other outcomes

  1. Change From Baseline in Adult Low Blood Sugar Survey (ALBSS) Score

    Time frame: Baseline, Week 72

  2. Change From Baseline in European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Score

    Time frame: Baseline, Week 72

  3. Change From Baseline in Mini-mental State Examination (MMSE) Score

    Time frame: Baseline, Week 72

07

Results

Posted Nov 23, 2016
Limitations and caveats
The trial was terminated per protocol due to lack of feasibility. All participants completed the first 24 weeks of the study. Some participants continued into the Core study. Data was assessed from Baseline to last participant visit, up to 72 weeks.

Participant flow

Participant flow — Overall Study
MilestoneStrategy A (Glucose-Dependent)Strategy B (Reference)
Started9993
Received at least one dose of study drug9893
Completed1415
Not completed8578
Withdrew: Lack of efficacy1829
Withdrew: Protocol violation77
Withdrew: Withdrawal by subject57
Withdrew: Adverse event52
Withdrew: No reason provided42
Withdrew: Death20
Withdrew: Physician decision01
Withdrew: Study terminated by sponsor4330
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia

Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c \> upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c \> upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associated with blood glucose ≤3.9 millimole per liter (mmol/L), or repeated asymptomatic hypoglycemia associated with blood glucose \<3.0 mmol/L. Success is defined as lacking of failure.

Time frame:
Baseline to last participant visit (up to 72 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
percentage of participantsStrategy A (Glucose-Dependent)Strategy B (Reference)
Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia64.5 (54.4 to 73.4)54.9 (44.6 to 64.9)
SecondaryPercentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy
Time frame:
Baseline to last participant visit (up to 72 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy
percentage of participantsStrategy A (Glucose-Dependent)Strategy B (Reference)
Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy2113
SecondaryNumber of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia
Time frame:
Baseline to last participant visit (up to 72 weeks)
Reported as:
Number · Participants
Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia
ParticipantsStrategy A (Glucose-Dependent)Strategy B (Reference)
Total Hypoglycemia1050
Severe Hypoglycemia00
Clinically Significant Hypoglycemia01
Symptomatic Hypoglycemia534
Asymptomatic Hypoglycemia830
Probable Symptomatic Hypoglycemia07
Unspecified Hypoglycemia27
Relative Hypoglycemia16
Nocturnal Hypoglycemia410
SecondaryChange From Baseline of Urinary Albumin to Creatinine Ratio

The Urinary Albumin to Creatinine Ratio is used in addition to Estimated Glomerular Filtration Rate (eGFR) to measure the incidence and progression of diabetic kidney disease.

Time frame:
Baseline, Week 72
Reported as:
Mean · milligram per millimole (mg/mmol)
Change From Baseline of Urinary Albumin to Creatinine Ratio
milligram per millimole (mg/mmol)Strategy A (Glucose-Dependent)Strategy B (Reference)
Change From Baseline of Urinary Albumin to Creatinine Ratio1.85 ± 22.991.85 ± 16.46
SecondaryChange From Baseline in Body Mass Index (BMI)
Time frame:
Baseline, Week 72
Reported as:
Mean · kilogram per square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
kilogram per square meter (kg/m^2)Strategy A (Glucose-Dependent)Strategy B (Reference)
Change From Baseline in Body Mass Index (BMI)-0.47 ± 1.560.20 ± 2.91
SecondaryChange From Baseline of Estimated Glomerular Filtration Rate (eGFR)

The eGFR is used in addition to the Urinary Albumin to Creatinine Ratio to measure the incidence and progression of diabetic kidney disease.

Time frame:
Baseline, Week 72
Reported as:
Mean · milliliter per minute/1.73 square meter
Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)
milliliter per minute/1.73 square meterStrategy A (Glucose-Dependent)Strategy B (Reference)
Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)-5.00 ± 13.64-5.88 ± 10.95
Other pre-specifiedChange From Baseline in Adult Low Blood Sugar Survey (ALBSS) Score
Time frame:
Baseline, Week 72

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Score
Time frame:
Baseline, Week 72

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Mini-mental State Examination (MMSE) Score
Time frame:
Baseline, Week 72

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Strategy A (Glucose-Dependent)—15/98 (15.3%)82/98 (83.7%)
Strategy B (Reference)—14/93 (15.1%)74/93 (79.6%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventStrategy A (Glucose-Dependent)Strategy B (Reference)
Atrial fibrillationCardiac disorders0/982/93
Myocardial infarctionCardiac disorders0/982/93
Cerebrovascular accidentNervous system disorders2/980/93
Cardiac failure congestiveCardiac disorders1/981/93
Lower gastrointestinal haemorrhageGastrointestinal disorders0/981/93
AppendicitisInfections and infestations0/981/93
PneumoniaInfections and infestations0/981/93
Respiratory tract infectionInfections and infestations0/981/93
ContusionInjury, poisoning and procedural complications0/981/93
Muscle ruptureInjury, poisoning and procedural complications0/981/93
Most frequent other events
Showing 10 of 229
Most frequent other events
EventStrategy A (Glucose-Dependent)Strategy B (Reference)
NasopharyngitisInfections and infestations10/9816/93
DiarrhoeaGastrointestinal disorders12/986/93
Back painMusculoskeletal and connective tissue disorders9/9811/93
Vitamin d deficiencyMetabolism and nutrition disorders9/983/93
Urinary tract infectionInfections and infestations3/988/93
Upper respiratory tract infectionInfections and infestations3/987/93
NauseaGastrointestinal disorders7/983/93
HeadacheNervous system disorders7/981/93
Oedema peripheralGeneral disorders1/986/93
OedemaGeneral disorders6/980/93

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Strategy A (Glucose-Dependent)Strategy B (Reference)Total
Mean70.7 ± 5.370.7 ± 4.470.7 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)Strategy A (Glucose-Dependent)Strategy B (Reference)Total
Female433477
Male5659115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Strategy A (Glucose-Dependent)Strategy B (Reference)Total
Hispanic or Latino353267
Not Hispanic or Latino6359122
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Strategy A (Glucose-Dependent)Strategy B (Reference)Total
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American61016
White9381174
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Strategy A (Glucose-Dependent)Strategy B (Reference)Total
Austria181432
Puerto Rico231639
United States293564
United Kingdom101121
Germany191736
08

Study locations

34 sites
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33175, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • Athens Primary Care
    Athens, Georgia 30606, United States
  • Herman Clinical Research, LLC
    Suwanee, Georgia 30024, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Iderc, P.L.C.
    Des Moines, Iowa 50314, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Mercy Health Research
    Saint Louis, Missouri 63141, United States
  • Southern New Hampshire Diabetes and Endocrinology
    Nashua, New Hampshire 03063, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Family Medical Associates
    Levittown, Pennsylvania 19056, United States
  • Carolina Health Specialists
    Myrtle Beach, South Carolina 29572, United States
  • Dallas Diabetes Endocrine Center
    Dallas, Texas 75230, United States
  • Rockwood Clinic Research Center
    Spokane, Washington 99202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Stefan Ob Stainz, A-8511, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5026, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vienna, A-1060, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wien, A 1210, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 10409, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dortmund, 44137, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22607, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55116, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Münster, 48145, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neuwied, 56564, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stuttgart, 70378, Germany
  • Manati Medical Center
    Manati, 00674, Puerto Rico
  • American Telemedicine Center
    San Juan, 00917-3104, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salford, Manchester M6 8HD, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dundee, Scotland DD1 9SY, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sheffield, South Yorkshire S5 7AU, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ipswich, Suffolk IP4 5PD, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M41 5SL, United Kingdom
09

References and documents

Publications

  • Heller SR, Pratley RE, Sinclair A, Festa A, Kiljanski J, Brusko CS, Duan R, Heine RJ. Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM). Diabetes Obes Metab. 2018 Jan;20(1):148-156. doi: 10.1111/dom.13051. Epub 2017 Aug 8. PubMed 28671753 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2014
First posted
Feb 26, 2014
Start
Feb 2014
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Nov 23, 2016
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02072096
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Feb 2014
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Nov 23, 2016
Last update
Oct 9, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion